| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c2765df456458a18b534f9fe447e18a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405 |
| filingDate |
2013-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c25ca28e6439cf5aa9a558c8dc59001a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44a7d10f9542edddabd8d6cbc489af44 |
| publicationDate |
2014-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014024663-A1 |
| titleOfInvention |
Atb(0,+) amino acid transporter as a drug target for treatment of estrogen receptor-positive breast cancer |
| abstract |
The present invention includes inhibitors of the amino acid transporter ATB 0,+ and methods of uses thereof for the treatment of estrogen receptor-positive breast cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016097299-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115052634-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021091950-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3034074-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022235805-A1 |
| priorityDate |
2012-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |